Company: HURA
Filing Date: 2025-05-07
Form Type: 8-K/A
Source: 0000950170-25-065860
Chunk: 1

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-07
Form: 8-K/A
Chunk 1
---
 Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

| Item 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |

On March 12, 2025, TuHURA Biosciences, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Initial Form 8-K”) to announce, among other things, the appointment of Dr. Craig Tendler to the Company’s Board of Directors (the “Board”) effective as of March 10, 2025. At the time the Initial Form 8-K was filed, the Board had not yet determined on which Board committees, if any, Dr. Tendler would serve. This Amendment No. 1 to the Initial Form 8-K is being filed solely to report that on May 5, 2025, the Board appointed Dr. Tendler to serve as a member of the Nominating and Corporate Governance Committee of the Board effective as of May 5, 2025. This Amendment No. 1 does not amend, update, or change any other items or disclosure contained in the Initial Form 8-K.

SIGNATURE Pursuant to the requirements of the Securities and Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

| May 7, 2025 |     | TuHURA Biosciences, Inc. 
 By:                      |     | /s/ Dan Dearborn |     |                         |
|:------------|:----|:-------------------------|:----|:-----------------|:----|:------------------------|
|             |     |                          |     | Name:            |     | Dan Dearborn            |
|             |     |                          |     | Title:           |     | Chief Financial Officer |